Methotrexate pharmacogenomics in rheumatoid arthritis: Introducing false-positive report probability

Rheumatology

Volumn 48, Issue 6, 2009, Pages 597-598

  Dervieux, Thierry ^a  

^a Cypress Bioscience Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; PURINE; SERINE; THREONINE;

AMINO ACID SUBSTITUTION; ANALYTICAL ERROR; COHORT ANALYSIS; DEMOGRAPHY; DISEASE DURATION; DRUG RESPONSE; EDITORIAL; ETHNICITY; FALSE POSITIVE RESULT; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LOW DRUG DOSE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROBABILITY; PROTEIN EXPRESSION; PURINE SYNTHESIS; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; FALSE POSITIVE REACTIONS; GENOTYPE; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; METHOTREXATE; MULTIENZYME COMPLEXES; NUCLEOTIDE DEAMINASES; PHARMACOGENETICS; PROBABILITY;

EID: 65849260738     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep060     Document Type: Editorial

References (20)

1. Lee YC, Cui J, Costenbader KH, Shadick NA, Weinblatt ME, Karlson EW. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology 2009;48:613-7.
2. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006;54:3095-103.
3. Dervieux T, Furst D, Lein DO et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: Results of a multicentred cross sectional observational study. Ann Rheum Dis 2005;64:1180-5.
4. Dervieux T, Furst D, Lein DO et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-74.
5. Wessels JA, Kooloos WM, de JR et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2006;54:2830-9.
6. Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006;54:1087-95.
7. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
8. Colhoun HM, McKeigue PM, Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet 2003;361:865-72.
9. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosyl amino-imidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985;82:4881-5.
10. Allegra CJ, Hoang K, Yeh GC, Drake JC, Baram J. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem 1987;262:13520-6.
11. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.
12. Morgan SL, Oster RA, Lee JY, Alarcon GS, Baggott JE. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheum 2004;50:3104-11.
13. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986;236:193-200.
14. Montesinos MC, Takedachi M, Thompson LF, Wilder TF, Fernandez P, Cronstein BN. The antiinflammatory mechanism of methotrexate depends on extra-cellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: Findings in a study of ecto-5'-nucleotidase gene-deficient mice. Arthritis Rheum 2007;56:1440-5.
15. Kaldis P, Cheng A, Solomon MJ. The effects of changing the site of activating phosphorylation in CDK2 from threonine to serine. J Biol Chem 2000;275:32578-84.
16. Boccalatte FE, Voena C, Riganti C et al. The enzymatic activity of 5'-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) is enhanced by NPM-ALK: New insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood. Advance Access published Oct 9, 2008, doi:113: 2776-2790.
17. van Ede AE, Laan RF, Blom HJ et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525-30.
18. Reed MC, Nijhout HF, Neuhouser ML et al. A mathematical model gives insights into nutritional and genetic aspects of folate-mediated one-carbon metabolism. J Nutr 2006;136:2653-61.
19. Quinlivan EP, Gregory JF III. Effect of food fortification on folic acid intake in the United States. Am J Clin Nutr 2003;77:221-5.
20. Marie S, Heron B, Bitoun P, Timmerman T, Van Den Berghe G, Vincent MF. AICA-ribosiduria: A novel, neurologically devastating inborn error of purine biosynthesis caused by mutation of ATIC. Am J Hum Genet 2004;74:1276-81.